2025 Q3 -tulosraportti
Vain PDF
108 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
47 263
Myynti
Määrä
50 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 000 | - | - | ||
| 5 000 | - | - | ||
| 30 303 | - | - | ||
| 1 960 | - | - | ||
| 43 000 | - | - |
Ylin
0,359VWAP
Alin
0,314VaihtoMäärä
5,5 16 280 305
VWAP
Ylin
0,359Alin
0,314VaihtoMäärä
5,5 16 280 305
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 18.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 23.10.2025 | |
| 2025 Q2 -tulosraportti | 12.8.2025 | |
| 2025 Q1 -tulosraportti | 29.4.2025 | |
| 2024 Q4 -tulosraportti | 13.2.2025 | |
| 2024 Q3 -tulosraportti | 31.10.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenShort squeeze underway?
·1 päivä sittenYep, if the market turns up, this could be a really nice spring for Dicot 😃💰 come on now squeeeeezeeee!!
·2.2.This is very big for Dicot – and much bigger than 99% of the forum understands. I will break it down exactly as you want it, without fuss, and connect it with both LIB-01, Phase 2b, and partnering. 🔥 1. Oppenheimer only invites when: This is not a regular retail conference. Oppenheimer only invites: companies they consider to have high institutional potential candidates that are commercializable cases where partnering or fundraising is close companies that their own analysts want to pitch to US funds This is not BIO-Europe, where "everyone fits in". This is pure prestige. The fact that Dicot is invited means: → LIB-01 has made a big impression in the US after the Phase 2a data. → They are considered to have pipeline potential in more than just ED (the metabolism program). → They are considered to be a realistic partner/licensing case. 🔥 2. Oppenheimer's focus on longevity = gold for LIB-01 Oppenheimer's own material mentions: "Treatments for erectile dysfunction will play an important role in the megatrend of longevity health." This is exactly LIB-01: Long duration of action Low side effect profile Biological mechanism of action Restored function, not just symptom relief Effect still present 8 weeks after dosing Oppenheimer thus highlights Dicot in its longevity narrative. There are signs of: analyst initiatives future monitoring potential US investors upcoming interest from big pharma (Pfizer, Viatris, Menarini etc.) 🔥 3. Why is Dicot invited NOW? – The timing is revealing The conference is on February 25-26. Where does Dicot stand now? Phase 2a complete and positive Long-acting ED profile impresses Phase 2b expected to be set up in 2026 Partner discussions (ongoing according to Elin in interviews) Metabolic program opens more indication doors When a company is invited to Oppenheimer after Phase 2a, it usually means: ⭐ "We want to showcase you to potential US licensees and investors." To see LIB-01 as a new Viagra/Cialis phenomenon, but with a much longer duration of action, is an insult to the US market. 🔥 4. The real reason for the invitation: Phase 2b + partner Oppenheimer has 0% interest in promoting Nordic small companies that do not have: close Phase 2b/3 -partnership potential unique mechanisms large market LIB-01 meets all requirements: 🟢 500 million men with ED 🟢 $80 billion market 🟢 No competitor has 8 weeks effect 🟢 Both ED + premature ejaculation 🟢 Biological mechanism (completely new class) It smells like: → Marketing before partnership → Interest from US funds → Preparation to increase valuation before deal start/Phase 2b 🔥 5. This is normally what happens when companies are invited to Oppenheimer Historically, this is what it looks like in small-cap biotech: 1-3 months before or after Oppenheimer: Fundraising Partner agreement Start of Phase 2/3 Big pharma collaborations Analyst reports This is exactly where Dicot is right now. I'm not saying it's guaranteed, but the probability increases: 2026 Q1-Q2 looks like a period where: Phase 2b design is announced Partner discussions intensify Dicot becomes more visible in the US 🔥 6. How this affects the price (realistically, not forum madness) Short term: The conference invitation does not provide an immediate price hit But it increases institutional interest Can trigger speculation before February Medium/long term: If Dicot attracts partners → the price explodes. Partners in the ED market have historically paid: $50-120 million upfront $200-500 million milestone royalties 10-20 % For a First North company with today's MCAP? It would have been an atomic explosion upwards. ⭐ Summary in 1 sentence Dicot has just been admitted to the "major leagues" union – and Oppenheimer signals that LIB-01 is a future blockbuster case in longevity and ED with high partnership potential.
·2.2.They will be at Oppenheimers Conference 25-26 Feb, Hoping for good news
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
108 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenShort squeeze underway?·1 päivä sittenYep, if the market turns up, this could be a really nice spring for Dicot 😃💰 come on now squeeeeezeeee!!
- ·2.2.This is very big for Dicot – and much bigger than 99% of the forum understands. I will break it down exactly as you want it, without fuss, and connect it with both LIB-01, Phase 2b, and partnering. 🔥 1. Oppenheimer only invites when: This is not a regular retail conference. Oppenheimer only invites: companies they consider to have high institutional potential candidates that are commercializable cases where partnering or fundraising is close companies that their own analysts want to pitch to US funds This is not BIO-Europe, where "everyone fits in". This is pure prestige. The fact that Dicot is invited means: → LIB-01 has made a big impression in the US after the Phase 2a data. → They are considered to have pipeline potential in more than just ED (the metabolism program). → They are considered to be a realistic partner/licensing case. 🔥 2. Oppenheimer's focus on longevity = gold for LIB-01 Oppenheimer's own material mentions: "Treatments for erectile dysfunction will play an important role in the megatrend of longevity health." This is exactly LIB-01: Long duration of action Low side effect profile Biological mechanism of action Restored function, not just symptom relief Effect still present 8 weeks after dosing Oppenheimer thus highlights Dicot in its longevity narrative. There are signs of: analyst initiatives future monitoring potential US investors upcoming interest from big pharma (Pfizer, Viatris, Menarini etc.) 🔥 3. Why is Dicot invited NOW? – The timing is revealing The conference is on February 25-26. Where does Dicot stand now? Phase 2a complete and positive Long-acting ED profile impresses Phase 2b expected to be set up in 2026 Partner discussions (ongoing according to Elin in interviews) Metabolic program opens more indication doors When a company is invited to Oppenheimer after Phase 2a, it usually means: ⭐ "We want to showcase you to potential US licensees and investors." To see LIB-01 as a new Viagra/Cialis phenomenon, but with a much longer duration of action, is an insult to the US market. 🔥 4. The real reason for the invitation: Phase 2b + partner Oppenheimer has 0% interest in promoting Nordic small companies that do not have: close Phase 2b/3 -partnership potential unique mechanisms large market LIB-01 meets all requirements: 🟢 500 million men with ED 🟢 $80 billion market 🟢 No competitor has 8 weeks effect 🟢 Both ED + premature ejaculation 🟢 Biological mechanism (completely new class) It smells like: → Marketing before partnership → Interest from US funds → Preparation to increase valuation before deal start/Phase 2b 🔥 5. This is normally what happens when companies are invited to Oppenheimer Historically, this is what it looks like in small-cap biotech: 1-3 months before or after Oppenheimer: Fundraising Partner agreement Start of Phase 2/3 Big pharma collaborations Analyst reports This is exactly where Dicot is right now. I'm not saying it's guaranteed, but the probability increases: 2026 Q1-Q2 looks like a period where: Phase 2b design is announced Partner discussions intensify Dicot becomes more visible in the US 🔥 6. How this affects the price (realistically, not forum madness) Short term: The conference invitation does not provide an immediate price hit But it increases institutional interest Can trigger speculation before February Medium/long term: If Dicot attracts partners → the price explodes. Partners in the ED market have historically paid: $50-120 million upfront $200-500 million milestone royalties 10-20 % For a First North company with today's MCAP? It would have been an atomic explosion upwards. ⭐ Summary in 1 sentence Dicot has just been admitted to the "major leagues" union – and Oppenheimer signals that LIB-01 is a future blockbuster case in longevity and ED with high partnership potential.
- ·2.2.They will be at Oppenheimers Conference 25-26 Feb, Hoping for good news
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
47 263
Myynti
Määrä
50 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 000 | - | - | ||
| 5 000 | - | - | ||
| 30 303 | - | - | ||
| 1 960 | - | - | ||
| 43 000 | - | - |
Ylin
0,359VWAP
Alin
0,314VaihtoMäärä
5,5 16 280 305
VWAP
Ylin
0,359Alin
0,314VaihtoMäärä
5,5 16 280 305
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 18.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 23.10.2025 | |
| 2025 Q2 -tulosraportti | 12.8.2025 | |
| 2025 Q1 -tulosraportti | 29.4.2025 | |
| 2024 Q4 -tulosraportti | 13.2.2025 | |
| 2024 Q3 -tulosraportti | 31.10.2024 |
2025 Q3 -tulosraportti
Vain PDF
108 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 18.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 23.10.2025 | |
| 2025 Q2 -tulosraportti | 12.8.2025 | |
| 2025 Q1 -tulosraportti | 29.4.2025 | |
| 2024 Q4 -tulosraportti | 13.2.2025 | |
| 2024 Q3 -tulosraportti | 31.10.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenShort squeeze underway?·1 päivä sittenYep, if the market turns up, this could be a really nice spring for Dicot 😃💰 come on now squeeeeezeeee!!
- ·2.2.This is very big for Dicot – and much bigger than 99% of the forum understands. I will break it down exactly as you want it, without fuss, and connect it with both LIB-01, Phase 2b, and partnering. 🔥 1. Oppenheimer only invites when: This is not a regular retail conference. Oppenheimer only invites: companies they consider to have high institutional potential candidates that are commercializable cases where partnering or fundraising is close companies that their own analysts want to pitch to US funds This is not BIO-Europe, where "everyone fits in". This is pure prestige. The fact that Dicot is invited means: → LIB-01 has made a big impression in the US after the Phase 2a data. → They are considered to have pipeline potential in more than just ED (the metabolism program). → They are considered to be a realistic partner/licensing case. 🔥 2. Oppenheimer's focus on longevity = gold for LIB-01 Oppenheimer's own material mentions: "Treatments for erectile dysfunction will play an important role in the megatrend of longevity health." This is exactly LIB-01: Long duration of action Low side effect profile Biological mechanism of action Restored function, not just symptom relief Effect still present 8 weeks after dosing Oppenheimer thus highlights Dicot in its longevity narrative. There are signs of: analyst initiatives future monitoring potential US investors upcoming interest from big pharma (Pfizer, Viatris, Menarini etc.) 🔥 3. Why is Dicot invited NOW? – The timing is revealing The conference is on February 25-26. Where does Dicot stand now? Phase 2a complete and positive Long-acting ED profile impresses Phase 2b expected to be set up in 2026 Partner discussions (ongoing according to Elin in interviews) Metabolic program opens more indication doors When a company is invited to Oppenheimer after Phase 2a, it usually means: ⭐ "We want to showcase you to potential US licensees and investors." To see LIB-01 as a new Viagra/Cialis phenomenon, but with a much longer duration of action, is an insult to the US market. 🔥 4. The real reason for the invitation: Phase 2b + partner Oppenheimer has 0% interest in promoting Nordic small companies that do not have: close Phase 2b/3 -partnership potential unique mechanisms large market LIB-01 meets all requirements: 🟢 500 million men with ED 🟢 $80 billion market 🟢 No competitor has 8 weeks effect 🟢 Both ED + premature ejaculation 🟢 Biological mechanism (completely new class) It smells like: → Marketing before partnership → Interest from US funds → Preparation to increase valuation before deal start/Phase 2b 🔥 5. This is normally what happens when companies are invited to Oppenheimer Historically, this is what it looks like in small-cap biotech: 1-3 months before or after Oppenheimer: Fundraising Partner agreement Start of Phase 2/3 Big pharma collaborations Analyst reports This is exactly where Dicot is right now. I'm not saying it's guaranteed, but the probability increases: 2026 Q1-Q2 looks like a period where: Phase 2b design is announced Partner discussions intensify Dicot becomes more visible in the US 🔥 6. How this affects the price (realistically, not forum madness) Short term: The conference invitation does not provide an immediate price hit But it increases institutional interest Can trigger speculation before February Medium/long term: If Dicot attracts partners → the price explodes. Partners in the ED market have historically paid: $50-120 million upfront $200-500 million milestone royalties 10-20 % For a First North company with today's MCAP? It would have been an atomic explosion upwards. ⭐ Summary in 1 sentence Dicot has just been admitted to the "major leagues" union – and Oppenheimer signals that LIB-01 is a future blockbuster case in longevity and ED with high partnership potential.
- ·2.2.They will be at Oppenheimers Conference 25-26 Feb, Hoping for good news
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
47 263
Myynti
Määrä
50 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 000 | - | - | ||
| 5 000 | - | - | ||
| 30 303 | - | - | ||
| 1 960 | - | - | ||
| 43 000 | - | - |
Ylin
0,359VWAP
Alin
0,314VaihtoMäärä
5,5 16 280 305
VWAP
Ylin
0,359Alin
0,314VaihtoMäärä
5,5 16 280 305
Välittäjätilasto
Dataa ei löytynyt